Request Trial
2 October 2026NewsIn-house counselMarisa Woutersen

What's AI best at? In-house teams are still learning

AI is helping legal and IP teams handle more work without adding headcount, but in-house counsel at LSPN Europe warn that knowing when not to rely on the technology is just as important as knowing how to use it.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Week Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Atif Choudhury at achoudhury@lifesciencesipreview.com 


More on this story

In-house counsel
WATCH: Genevant IP director on tackling UPC-EPO opposition divide
1 October 2026   With patent validity increasingly being fought over in both the UPC and EPO, Genevant Sciences’ Stephan Kutik talks to LSIPR about keeping parallel proceedings aligned and why teamwork matters.
In-house counsel
CIPA Congress: Sustainability is essential for the profession and the planet
18 September 2026   At an event attended by patent experts and judges from Europe, the US and China, delegates gathered in the innovation hub of Manchester, UK, to debate the theme of sustainability "in its broadest sense". Sarah Speight was there to hear ideas spanning the commercialisation of clean tech, to ensuring the patent profession’s resilience in a time of colossal change.
In-house counsel
Exclusive: Winston Taylor’s UK head of IP on pitching $1.75bn firm’s ‘humble, but lethal’ practice
4 August 2026   A transatlantic firm with intellectual property at its heart—what’s not to like? The firm’s 30-year veteran tells WIPR why leading a recruitment drive is a “big responsibility” as the combined firm looks to out-scale the opposition.


Editor's picks

Inside the deal boom: LSIPR’s five-part M&A series—all in one place
Regulation & Industry
Inside the deal boom: LSIPR’s five-part M&A series—all in one place
17 September 2026

Editor's picks

Regulation & Industry
Inside the deal boom: LSIPR’s five-part M&A series—all in one place
17 September 2026
Biotech
Exelixis locks down cancer drug exclusivity until 2030 with Fed Circ win
1 September 2026
Regulation & Industry
The buyers' wishlist: What makes a life sciences deal stack up?
25 August 2026
MedTech
Abbott fends off Chinese rival’s patent challenge at UPC
18 August 2026
Regulation & Industry
Where Big Pharma is betting big in the M&A boom
29 July 2026
Regulation & Industry
Buying the brains: Why is Big Pharma shopping for innovation?
27 July 2026

More features

WATCH: Genevant IP director on tackling UPC-EPO opposition divide
5 LSPN takeaways: What’s keeping Europe’s IP teams on their toes?
Lilly loses Fed Circ rehearing bid, sparking enablement questions
Westlaw publisher scores landmark AI copyright win in US appeals court
Scientist and Chinese biotech targeted by Beam in secrets suit
Clifford Chance recruits new head of Asia-Pac
Takeda sees off UK challenge to Elvanse SPC
Conley Rose welcomes back former employee with legal and business nous